Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Equity Average (2020 - 2025)

Historic Equity Average for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$4.0 million.

  • Insight Molecular Diagnostics' Equity Average fell 12498.3% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.0 million, marking a year-over-year decrease of 12498.3%. This contributed to the annual value of $4.1 million for FY2024, which is 8503.65% down from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Equity Average is -$4.0 million, which was down 12498.3% from $5.7 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Equity Average high stood at $104.6 million for Q2 2021, and its period low was -$4.0 million during Q3 2025.
  • In the last 5 years, Insight Molecular Diagnostics' Equity Average had a median value of $29.0 million in 2023 and averaged $39.5 million.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Equity Average soared by 17459.92% in 2021 and then tumbled by 12498.3% in 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Equity Average (Quarter) stood at $82.3 million in 2021, then plummeted by 32.46% to $55.6 million in 2022, then crashed by 47.79% to $29.0 million in 2023, then tumbled by 104.42% to -$1.3 million in 2024, then tumbled by 215.96% to -$4.0 million in 2025.
  • Its Equity Average stands at -$4.0 million for Q3 2025, versus $5.7 million for Q2 2025 and -$1.0 million for Q1 2025.